Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.106 EUR
−3.52 M EUR
4.64 M EUR
33.04 M
About ABIONYX PHARMA
Sector
CEO
Cyrille Tupin
Headquarters
Balma
Website
Founded
2005
ISIN
FR0012616852
FIGI
BBG00JHW6Y35
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. It specializes in the development of treatment for cardiovascular and metabolic disorders. The company was founded by Jean-Louis Dasseux and William F. Brinkerhoff on March 24, 2005 and is headquartered in Balma, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0RAG is 1.362 EUR — it has increased by 0.29% in the past 24 hours. Watch ABIONYX PHARMA EUR0.05 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ABIONYX PHARMA EUR0.05 stocks are traded under the ticker 0RAG.
We've gathered analysts' opinions on ABIONYX PHARMA EUR0.05 future price: according to them, 0RAG price has a max estimate of 11.50 EUR and a min estimate of 11.50 EUR. Watch 0RAG chart and read a more detailed ABIONYX PHARMA EUR0.05 stock forecast: see what analysts think of ABIONYX PHARMA EUR0.05 and suggest that you do with its stocks.
0RAG reached its all-time high on Jan 4, 2022 with the price of 3.266 EUR, and its all-time low was 0.374 EUR and was reached on May 24, 2019. View more price dynamics on 0RAG chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0RAG stock is 0.59% volatile and has beta coefficient of −0.86. Track ABIONYX PHARMA EUR0.05 stock price on the chart and check out the list of the most volatile stocks — is ABIONYX PHARMA EUR0.05 there?
Today ABIONYX PHARMA EUR0.05 has the market capitalization of 42.31 M, it has decreased by −1.45% over the last week.
Yes, you can track ABIONYX PHARMA EUR0.05 financials in yearly and quarterly reports right on TradingView.
ABIONYX PHARMA EUR0.05 is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
0RAG net income for the last half-year is −2.09 M EUR, while the previous report showed −1.27 M EUR of net income which accounts for −64.41% change. Track more ABIONYX PHARMA EUR0.05 financial stats to get the full picture.
No, 0RAG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 61.00 employees. See our rating of the largest employees — is ABIONYX PHARMA EUR0.05 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABIONYX PHARMA EUR0.05 EBITDA is −4.77 M EUR, and current EBITDA margin is −108.90%. See more stats in ABIONYX PHARMA EUR0.05 financial statements.
Like other stocks, 0RAG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIONYX PHARMA EUR0.05 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABIONYX PHARMA EUR0.05 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABIONYX PHARMA EUR0.05 stock shows the buy signal. See more of ABIONYX PHARMA EUR0.05 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.